{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:59:55Z","timestamp":1790197195981,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100013822","name":"Kurdistan University Of Medical Sciences","doi-asserted-by":"publisher","award":["IR.MUK.REC.1397\/348"],"award-info":[{"award-number":["IR.MUK.REC.1397\/348"]}],"id":[{"id":"10.13039\/501100013822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"DOI":"10.1007\/s11011-026-01991-w","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:14:01Z","timestamp":1790147641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Randomized, placebo-controlled trial of N-acetylcysteine in Parkinson\u2019s disease patients: a pilot study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5288-6243","authenticated-orcid":false,"given":"Bahar Moasses","family":"Ghafari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6909-1420","authenticated-orcid":false,"given":"Aref","family":"Rajabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7607-6859","authenticated-orcid":false,"given":"Parham","family":"Geramifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8388-4490","authenticated-orcid":false,"given":"Asrin","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1912-384X","authenticated-orcid":false,"given":"Helia Karimi","family":"Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-8040","authenticated-orcid":false,"given":"Khaled","family":"Rahmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0720-3487","authenticated-orcid":false,"given":"Arman","family":"Rahimmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"4","key":"1991_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"JD Steinmetz","year":"2024","unstructured":"Steinmetz JD, Seeher KM, Schiess N et al (2024) Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 23(4):344\u2013381","journal-title":"Lancet Neurol"},{"issue":"5","key":"1991_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E et al (2021) Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol 20(5):385\u2013397","journal-title":"Lancet Neurol"},{"issue":"4","key":"1991_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/JPD-130230","volume":"3","author":"V Dias","year":"2013","unstructured":"Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in Parkinson\u2019s disease. J Parkinsons Dis 3(4):461\u2013491","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"1991_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/jcp.26865","volume":"234","author":"K Hassanzadeh","year":"2019","unstructured":"Hassanzadeh K, Rahimmi A (2019) Oxidative stress and neuroinflammation in the story of Parkinson\u2019s disease. J Cell Physiol 234(1):23\u201332","journal-title":"J Cell Physiol"},{"issue":"4","key":"1991_CR5","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.celrep.2017.12.092","volume":"22","author":"SJ Chinta","year":"2018","unstructured":"Chinta SJ et al (2018) Cellular senescence is induced by paraquat and contributes to neuropathology linked to Parkinson\u2019s disease. Cell Rep 22(4):930\u2013940","journal-title":"Cell Rep"},{"issue":"15","key":"1991_CR6","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1212\/WNL.0b013e318232ab4c","volume":"77","author":"L Parkkinen","year":"2011","unstructured":"Parkkinen L, O\u2019Sullivan SS, Kuoppam\u00e4ki M et al (2011) Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 77(15):1420\u20131426","journal-title":"Neurology"},{"issue":"1","key":"1991_CR7","doi-asserted-by":"publisher","first-page":"39516","DOI":"10.1038\/s41598-025-23376-2","volume":"15","author":"EA Backman","year":"2025","unstructured":"Backman EA, Luntamo L, Vahlberg T, Gardberg M, Kaasinen V (2025) Levodopa exposure and nigral neuroinflammation in parkinsonian disorders: a postmortem study of 63 cases. Sci Rep 15(1):39516","journal-title":"Sci Rep"},{"key":"1991_CR8","doi-asserted-by":"publisher","first-page":"105065","DOI":"10.1016\/j.phrs.2020.105065","volume":"161","author":"G Bj\u00f8rklund","year":"2020","unstructured":"Bj\u00f8rklund G et al (2020) Preventive treatments to slow substantia nigra damage and Parkinson\u2019s disease progression. Pharmacol Res 161:105065","journal-title":"Pharmacol Res"},{"key":"1991_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.brainresbull.2015.02.007","volume":"113","author":"A Rahimmi","year":"2015","unstructured":"Rahimmi A et al (2015) N-acetylcysteine prevents rotenone-induced Parkinson\u2019s disease in rat. Brain Res Bull 113:34\u201340","journal-title":"Brain Res Bull"},{"issue":"7","key":"1991_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.nut.2007.05.004","volume":"23","author":"CM Chen","year":"2007","unstructured":"Chen CM et al (2007) Antioxidative and anti-inflammatory effects of four cysteine-containing agents in MPTP mice. Nutrition 23(7):589\u2013597","journal-title":"Nutrition"},{"issue":"7","key":"1991_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/10715762.2018.1468564","volume":"52","author":"G Aldini","year":"2018","unstructured":"Aldini G et al (2018) N-Acetylcysteine as an antioxidant and disulphide breaking agent. Free Radic Res 52(7):751\u2013762","journal-title":"Free Radic Res"},{"issue":"4","key":"1991_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2174\/1389200217666151210125918","volume":"17","author":"M Mart\u00ednez-Banaclocha","year":"2016","unstructured":"Mart\u00ednez-Banaclocha M (2016) Cysteine Network dysregulation in Parkinson\u2019s disease: role of N-acetylcysteine. Curr Drug Metab 17(4):368\u2013385","journal-title":"Curr Drug Metab"},{"issue":"2","key":"1991_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/jcph.1008","volume":"58","author":"LD Coles","year":"2018","unstructured":"Coles LD et al (2018) Repeated-dose oral N-acetylcysteine in Parkinson\u2019s disease. J Clin Pharmacol 58(2):158\u2013167","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1991_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/WNF.0b013e31829ae713","volume":"36","author":"MJ Holmay","year":"2013","unstructured":"Holmay MJ et al (2013) N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol 36(4):103\u2013106","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"1991_CR15","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cpt.1548","volume":"106","author":"DA Monti","year":"2019","unstructured":"Monti DA et al (2019) N-acetyl cysteine is associated with dopaminergic improvement in Parkinson\u2019s disease. Clin Pharmacol Ther 106(4):884\u2013890","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1991_CR16","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/mds.10473","volume":"18","author":"Movement Disorder Society Task Force","year":"2003","unstructured":"Movement Disorder Society Task Force (2003) The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18(7):738\u2013750","journal-title":"Mov Disord"},{"issue":"1","key":"1991_CR17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1109\/TNS.1978.4329385","volume":"25","author":"LT Chang","year":"1978","unstructured":"Chang LT (1978) A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 25(1):638\u2013643","journal-title":"IEEE Trans Nucl Sci"},{"key":"1991_CR18","doi-asserted-by":"crossref","unstructured":"Burcham PC (2014) Target-organ toxicity: liver and kidney. An Introduction to Toxicology. Springer, pp 151\u2013187","DOI":"10.1007\/978-1-4471-5553-9_6"},{"issue":"6","key":"1991_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3390\/antiox10060967","volume":"10","author":"MCS Ten\u00f3rio","year":"2021","unstructured":"Ten\u00f3rio MCS et al (2021) N-acetylcysteine (NAC): impacts on human health. Antioxidants 10(6):967","journal-title":"Antioxidants"},{"issue":"24","key":"1991_CR20","doi-asserted-by":"publisher","first-page":"e2238","DOI":"10.1212\/WNL.0000000000006643","volume":"91","author":"P Turcano","year":"2018","unstructured":"Turcano P et al (2018) Levodopa-induced dyskinesia in Parkinson disease. Neurology 91(24):e2238\u2013e2243","journal-title":"Neurology"},{"issue":"6","key":"1991_CR21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/mds.27216","volume":"33","author":"CW Olanow","year":"2018","unstructured":"Olanow CW, Stocchi F (2018) Levodopa: a new look at an old friend. Mov Disord 33(6):859\u2013866","journal-title":"Mov Disord"},{"issue":"8","key":"1991_CR22","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.1007\/s11033-022-07345-w","volume":"49","author":"A Rahimmi","year":"2022","unstructured":"Rahimmi A et al (2022) The neuroprotective roles of dietary micronutrients on Parkinson\u2019s disease. Mol Biol Rep 49(8):8051\u20138060","journal-title":"Mol Biol Rep"},{"issue":"1","key":"1991_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/jnnp.2008.157370","volume":"81","author":"G K\u00e4gi","year":"2010","unstructured":"K\u00e4gi G, Bhatia KP, Tolosa E (2010) The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 81(1):5\u201312","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"1991_CR24","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG et al (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19(9):1020\u20131028","journal-title":"Mov Disord"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01991-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-026-01991-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01991-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:02:49Z","timestamp":1790193769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-026-01991-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1991"],"URL":"https:\/\/doi.org\/10.1007\/s11011-026-01991-w","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"5 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from all patients. The Ethics Committee of Kurdistan University of Medical Sciences approved the protocol (IR.MUK.REC.1397.348). Registered at IRCT (IRCT20181006041247N1) and ClinicalTrials.gov (NCT07093944).","order":1,"name":"Ethics","label":"Ethics and consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"224"}}